These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16723139)

  • 1. Investigation of the age-at-onset heterogeneity in type 1 diabetes through mathematical modeling.
    Wang X; He Z; Ghosh S
    Math Biosci; 2006 Sep; 203(1):79-99. PubMed ID: 16723139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation.
    Khadra A; Santamaria P; Edelstein-Keshet L
    J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying immunotherapy for the management of autoimmune diabetes.
    Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
    Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rehabilitation of adaptive immunity and regeneration of beta cells.
    Pasquali L; Fan Y; Trucco M; Ringquist S
    Trends Biotechnol; 2006 Nov; 24(11):516-22. PubMed ID: 16963140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of residual beta cells and islet autoimmunity during increasing duration of diabetes in NOD mice and experimental approaches toward reversing new-onset disease with bioactive peptides.
    Reddy S; Cheung CC; Chai RC; Rodrigues JA
    Ann N Y Acad Sci; 2008 Dec; 1150():171-6. PubMed ID: 19120289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune mechanisms in type 1 diabetes.
    Knip M; Siljander H
    Autoimmun Rev; 2008 Jul; 7(7):550-7. PubMed ID: 18625444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.
    Yang Z; Chen M; Carter JD; Nunemaker CS; Garmey JC; Kimble SD; Nadler JL
    Biochem Biophys Res Commun; 2006 Jun; 344(3):1017-22. PubMed ID: 16643856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
    Xia CQ; Peng R; Qiu Y; Annamalai M; Gordon D; Clare-Salzler MJ
    Diabetes; 2007 Aug; 56(8):2116-23. PubMed ID: 17496235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune intervention for type 1 diabetes mellitus.
    Skyler JS
    Int J Clin Pract Suppl; 2011 Feb; (170):61-70. PubMed ID: 21323814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does physiological beta cell turnover initiate autoimmune diabetes in the regional lymph nodes?
    Pearl-Yafe M; Iskovich S; Kaminitz A; Stein J; Yaniv I; Askenasy N
    Autoimmun Rev; 2006 May; 5(5):338-43. PubMed ID: 16782559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in type 1 diabetes.
    Taplin CE; Barker JM
    Autoimmunity; 2008 Feb; 41(1):11-8. PubMed ID: 18176860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different islet protein expression profiles during spontaneous diabetes development vs. allograft rejection in BB-DP rats.
    Christensen UB; Larsen PM; Fey S; Karlsen AE; Pociot F; Nerup J; Sparre T
    Autoimmunity; 2006 Jun; 39(4):315-21. PubMed ID: 16891220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale.
    Pickersgill LM; Mandrup-Poulsen TR
    Diabetes Metab Res Rev; 2009 May; 25(4):321-4. PubMed ID: 19405081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of HLA-A24, -DQA1*03, and -DR9 contributes to acute-onset and early complete beta-cell destruction in type 1 diabetes: longitudinal study of residual beta-cell function.
    Nakanishi K; Inoko H
    Diabetes; 2006 Jun; 55(6):1862-8. PubMed ID: 16731854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Of mice and men: use of animal models to identify possible interventions for the prevention of autoimmune type 1 diabetes in humans.
    Serreze DV; Chen YG
    Trends Immunol; 2005 Nov; 26(11):603-7. PubMed ID: 16140038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?
    Li DS; Warnock GL; Tu HJ; Ao Z; He Z; Lu H; Dai LJ
    Life Sci; 2009 Oct; 85(15-16):549-56. PubMed ID: 19747492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological aspects of 'fulminant type 1 diabetes'.
    Nagata M; Moriyama H; Kotani R; Yasuda H; Kishi M; Kurohara M; Hara K; Yokono K
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S99-103. PubMed ID: 17478003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysrulation of T cell peripheral tolerance in type 1 diabetes.
    Tisch R; Wang B
    Adv Immunol; 2008; 100():125-49. PubMed ID: 19111165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of T cells in the pathogenesis of type I diabetes mellitus: structure analysis of complementarity determining region 3 of circulating T cells].
    Sakumai M; Yachie A; Kasahara Y
    Rinsho Byori; 2007 Feb; 55(2):112-9. PubMed ID: 17390713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation among mannose-binding lectin 2 genotype, beta-cell autoantibodies, and risk for type 1 diabetes in Finnish children.
    Aittoniemi J; Turpeinen H; Tiittanen M; Knip M; Simell O; Ilonen J; Vaarala O
    Hum Immunol; 2008 Feb; 69(2):108-11. PubMed ID: 18361935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.